Preclinical toxicology and safety pharmacology of the first-in-class GADD45ß/MKK7 inhibitor and clinical candidate, DTP3. (2019)
Attributed to:
Treating Multiple Myeloma by Targeting the NF-Kappa-B Pathway with Gadd45-Beta/MKK7 Inhibitors
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.toxrep.2019.04.006
PubMed Identifier: 31080744
Publication URI: http://europepmc.org/abstract/MED/31080744
Type: Journal Article/Review
Volume: 6
Parent Publication: Toxicology reports
ISSN: 2214-7500